JCRファーマ株式会社 develops and provides biopharmaceuticals for rare diseases, self-described as specializing in rare disease areas.

JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.

4552

JP:CO:JCRPHARM

JCRファーマ株式会社

Last Close

666.00

25/09 06:15

Market Cap

77.50B

Beta: -

Volume Today

755.60K

Avg: -

locale

market

industry

website

ipo date

competitor of

Metrics